<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101448</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU7</org_study_id>
    <nct_id>NCT04101448</nct_id>
  </id_info>
  <brief_title>Prevalence of Bronchiectasis in COPD Patients</brief_title>
  <official_title>Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The identification of bronchiectasis in COPD has been defined as a different clinical COPD
      phenotype with greater symptomatic severity, more frequent chronic bronchial infection and
      exacerbations, and poor prognosis. A causal association has not yet been proven, but it is
      biologically plausible that COPD, and particularly the infective and exacerbator COPD
      phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any
      mere association or comorbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The relationship between bronchiectasis and COPD has generated several questions. Is there
      any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of
      bronchiectasis have an impact on the clinical characteristics, prognosis, or response to
      treatment in COPD, to the extent that it can be considered a distinct clinical phenotype?
      Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a
      consequence of the disease's natural history? Is there a causal relationship between COPD and
      bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible
      for this relationship? And, finally, what is the role of chronic bronchial infection and
      exacerbations in this relationship?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Bronchiectasis in COPD</measure>
    <time_frame>1 year</time_frame>
    <description>percentage of bronchiectasis diagnosed by CT chest in COPD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact of bronchiectasis on COPD exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>number of exacerbations treated in or out of hospitals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of bronchiectasis on COPD hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>number of hospital admissions with acute exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of bronchiectasis on COPD intensive care admission</measure>
    <time_frame>1 year</time_frame>
    <description>number of admissions in respiratory ICU and need for mechanical or non invasive ventilation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bronchiectasis</condition>
  <condition>Chronic Obstruct Airways Disease</condition>
  <condition>Prognosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>COPD patients with bronchiectasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>COPD patients without bronchiectasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prevalence</intervention_name>
    <description>percentage of bronchectasis in COPD and its effect as prognostic measure</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients diagnosed based on GOLD criteria 2019 with chest CT finding of bronchiectasis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients based on GOLD 2019 criteria, stable or in exacerbation

        Exclusion Criteria:

          -  acute pneumonia within 2 months

          -  malignancy

          -  congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome).

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Aliae Mohamed-Hussein</last_name>
    <phone>01222302352</phone>
    <phone_ext>002</phone_ext>
    <email>aliaehussein@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AssiutU</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliae AR Mohamed-Hussein</last_name>
      <phone>+201222302352</phone>
      <email>aliaehussein@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 22, 2019</study_first_submitted>
  <study_first_submitted_qc>September 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aliae AR Mohamed Hussein</investigator_full_name>
    <investigator_title>Professor of Pulmonology</investigator_title>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>COPD</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

